Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Mutation Analysis
Acyl-CoA Dehydrogenase gene (ACADM) is located on chromosome 1p31 and contains 12 exons. The c.985A>G missense mutation (K304E) in exon 11 represents 80% and 90% of all mutated alleles in the European and American populations, respectively. Approximately 50 percent of patients are homozygous for the c.985A>G mutation; however, 40 percent are compound heterozygotes with one copy of c.985A>G and a rare mutation on their other allele. Other rare mutations have been spread throughout the gene; these may result in mild MCAD deficiency. The enzyme plays a role in mitochondrial fatty acid beta-oxidation, fueling hepatic ketogenesis during periods of high-energy demand after hepatic glycogen stores have been depleted.
Therefore, MCAD deficiency results in the accumulation of medium-chain fatty acids and is the most frequently diagnosed beta-oxidation defect. This enzyme defect is inherited in an autosomal recessive fashion. Affected individuals appear normal at birth and typically experience their first acute metabolic episode at an early age (before two years of age). These episodes are usually triggered by prolonged fasting, malnutrition or infections, and other common pediatric illnesses. MCAD deficiency has been associated with sudden infant death syndrome. Disease episodes are common in adults, and are triggered mostly by metabolic problems, thyroid disorders, surgery, improper diet, heavy physical exertion and/ or alcohol use. Between attacks, individuals show no symptoms.
Hperoctanoylcarnitinaemia is the most common biomarker for MCAD deficiency. Although MCAD deficiency is potentially fatal, it is relatively easy to treat, and early diagnosis significantly improves the outcome. It causes hypoketotic hypoglycemia and the most important symptoms are lethargy, seizures, and coma associated with low blood glucose. Complications include brain damage, fatty infiltration of the liver, Reye-like syndrome, and hepatomegaly. A screening test is performed on filter paper blood spot samples from newborns.
- As an aid in diagnosis of early Reye-like syndrome
- Newborn screen for MCAD deficiency
- Diagnostic testing for parents and siblings of a proband homozygous for c.985A>G
- Carrier screening for at-risk relatives with family history of c.985A>G.
- Carrier screening for the reproductive partner of affected individuals with MCAD deficiency or individual that are carriers
- Diagnostic testing for patients with clinical and/or biochemical evidence of MCAD deficiency with confirmed mutations on the ACADM gene.
- Can be used for diagnosis of MCAD deficiency in autopsy cases
The detection of two severe ACADM gene mutations predicts MCAD deficiency and disease.
Compound heterozygosity for the c.985A>G mutation and the mild c.199T>C may produce an abnormal acylcarnitine profile If a mutation is detected in a patient without disease or symptoms, the patient is considered to be a carrier for classic MCAD deficiency.
If one mild mutation is detected in a patient without disease and symptoms, the patient is predicted to be at least a carrier for mild MCAD deficiency.
In questionable cases, samples with negative result for 985A>G mutation should be sent for direct DNA sequencing.
Note: False negatives are rare but do occur due to rare polymorphisms and unusual mutations.
Negative for mutation analyzed (Mutation not detected)
Blood
Filter paper blood spot sample is done routinely after birth.
In adulthood, whole blood is collected in purple top tube (EDTA), or ACD blue top tube.
Stability
- Ambient: 24 hours
- Refrigerated: 7 days
Note: It is important to submit the patient biochemical profile to include urine acylglycines, plasma acylcarnitines, fatty acid profile and urine organic acids, as this information will influence interpretation of the test.
- Scand J Clin Lab Invest Suppl. 1995;220:9-25. [PMID: 7652482]
- Hum Mutat. 1992;1(4):271-9. [PMID: 1363805]
- J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):370-7. [PMID: 16763904]
- Eur J Pediatr. 1992 Mar;151(3):154-9. [PMID: 1601002]
- Mol Genet Metab. 2012;106:175-88. [PMID: 22542437]
- Orphanet J Rare Dis. 2012 May 25;7(1):30. [PMID: 22630369]
- Strauss AW et al. Fatty-acid oxidation defects K. Sarafoglou (Ed.), Pediatric Endocrinology and Metabolism (2009), 51–70.